Specialty
Certifications
Medical Oncology
American Board of Internal Medicine
Clinical Focus
Education
MD, Yale University School of Medicine
Residency, Internal Medicine
Mount Sinai HospitalFellowship, Hematology/Oncology
Columbia- Presbyterian Medical Center
Biography
Dr. Kerin Adelson is a medical oncologist specializing in breast cancer medicine. Her clinical practice is dedicated to treating all aspects of breast cancer including: breast cancer prevention in women at high risk for breast cancer, management of ductal carcinoma in situ, adjuvant (post-operative treatment) and neo-adjuvant (pre-operative) treatment of invasive breast cancer, and management of advanced stage disease. While focused on giving state-of-the art breast cancer care, Dr. Adelson is also very sensitive to the intense psychological stress her patients experience with a breast cancer diagnosis.
Dr. Adelson’s research is focused on overcoming
biologic mechanisms of resistance to hormonal modulation. She is the principal investigator of
the multi-site NCI 8457, A randomized phase II study of fulvestrant vs.
fulvestrant plus bortezomib in metastatic ER+ breast cancer. The rationale for this study came from
the work of Dr. Doris Germain, a basic scientist at Mt. Sinai with whom she
closely collaborates.
Clinical Trials:
NCI 8457: NCI 8457, A randomized phase II study of fulvestrant vs. fulvestrant plus bortezomib in metastatic ER+ breast cancer
NCI 8475: Phase I study of ABT-888, PARP Inhibitor, and Peglylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic and Breast Cancer
Soon to open: MA32: A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Media:
FOX news interview. Sparing patients from chemotherapy.
http://video.foxnews.com/v/4390037/sparing-patients-from-chemotherapy/
Clinical Trials
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Adelson during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Genomic Health, Inc.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Genomic Health, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor E Level Room Room ABE-10
1428 Madison Avenue
New York, NY 10029
Dubin Breast Center
1176 Fifth Avenue
New York, NY 10029
- Monday 9:00am - 5:00pm
- Tuesday 9:00am - 5:00pm
- Wednesday 9:00am - 5:00pm
- Thursday 9:00am - 5:00pm
- Friday 9:00am - 5:00pm
- Spanish
- 1199 National Benefit Fund
- Blue Cross/ Blue Shield
- Blue Cross/ Blue Shield - HMO
- CIGNA Healthcare HMO
- Cigna
- Fidelis Care NY
- Group Health Insurance, Inc.
- HealthNet
- Island Group
- Magnacare
- Medicaid
- Medicare
- Neighborhood Health Providers, LLC
- Travel Care Services
- United Healthcare
- Master Card
- Visa